IPHA
Innate Pharma
NASDAQ: IPHA · HEALTHCARE · BIOTECHNOLOGY
$1.36
-4.47% today
Updated 2026-06-05
Market cap
$170.90M
P/E ratio
—
P/S ratio
18.98x
EPS (TTM)
$-0.64
Dividend yield
—
52W range
$1 – $3
Volume
0.1M
Innate Pharma (IPHA) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+41.1%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+100.0%
Most recent quarter
When is the next earnings report?
Reporting date
December 31, 2025
Consensus EPS estimate
$-0.14
Fiscal period ending
2025-12-31
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+27.2%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+59.6%
2026-05-13
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-05-13 | $0.00 | +100.0% | $1.36 | $2.17 | +59.6% |
| 2025-11-13 | $-0.14 | -1.6% | $1.92 | $1.82 | -5.2% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | $-0.16 | $0.00 | +100.0% | $-2.07M | -851.1% |
| 2025-12-31 | $-0.14 | — | — | $-2.07M | — |
| 2025-09-30 | $-0.14 | $-0.14 | -1.6% | — | — |
| 2025-06-30 | — | $-0.30 | — | $4.86M | -60.6% |
| 2025-03-31 | $-0.40 | $-0.30 | +25.0% | $276000.00 | -98.3% |
| 2024-12-31 | $-0.40 | $-0.30 | +25.0% | — | — |
| 2024-09-30 | $0.00 | $0.00 | — | — | — |
| 2024-06-30 | $-0.38 | $-0.31 | +19.4% | $12.35M | -65.1% |
| 2024-03-31 | $0.00 | $0.00 | — | $16.56M | — |
| 2023-12-31 | $-0.41 | $-0.12 | +71.9% | $21.44M | — |
| 2023-09-30 | $0.00 | $0.00 | — | $10.72M | — |
| 2023-06-30 | $-0.14 | $0.02 | +114.6% | $35.34M | — |
Frequently asked questions
When does Innate Pharma report next earnings?
Innate Pharma (IPHA) is scheduled to report earnings on December 31, 2025. The consensus EPS estimate is $-0.14.
Has Innate Pharma beaten earnings estimates?
Innate Pharma has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, averaging a +41.1% surprise over the last 3. A consistent beat record suggests management guides conservatively and the business has predictable momentum, which tends to support the stock through earnings season.
How does IPHA stock react to earnings?
IPHA has moved an average of +27.2% the day after earnings over its last 2 reports, finishing higher after 1 of them. Next-day moves show how the market digests results in the short term, and repeated dips on strong reports usually mean expectations were already priced in.